Mirum Net Tangible Assets from 2010 to 2026
| MIRM Stock | USD 103.10 1.09 1.07% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 95.5 M | Current Value 103.3 M | Quarterly Volatility 66.9 M |
Check Mirum Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mirum Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 16.7 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 28.5 M, as well as many indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0 or PTB Ratio of 8.23. Mirum financial statements analysis is a perfect complement when working with Mirum Pharmaceuticals Valuation or Volatility modules.
Mirum | Net Tangible Assets | Build AI portfolio with Mirum Stock |
Evaluating Mirum Pharmaceuticals's Net Tangible Assets across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Mirum Pharmaceuticals's fundamental strength.
Latest Mirum Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Mirum Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Mirum Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mirum Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Mirum Net Tangible Assets Regression Statistics
| Arithmetic Mean | 40,954,375 | |
| Coefficient Of Variation | 163.34 | |
| Mean Deviation | 61,694,867 | |
| Median | (17,313,000) | |
| Standard Deviation | 66,896,800 | |
| Sample Variance | 4475.2T | |
| Range | 189.4M | |
| R-Value | 0.77 | |
| Mean Square Error | 1967.6T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | 10,156,700 | |
| Total Sum of Squares | 71602.9T |
Mirum Net Tangible Assets History
About Mirum Pharmaceuticals Financial Statements
Mirum Pharmaceuticals investors utilize fundamental indicators, such as Net Tangible Assets, to predict how Mirum Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 95.5 M | 103.3 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Mirum Pharmaceuticals Correlation against competitors. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Biotechnology sector continue expanding? Could Mirum diversify its offerings? Factors like these will boost the valuation of Mirum Pharmaceuticals. Expected growth trajectory for Mirum significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mirum Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.84) | Revenue Per Share | Quarterly Revenue Growth 0.472 | Return On Assets | Return On Equity |
Understanding Mirum Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Mirum's accounting equity. The concept of intrinsic value - what Mirum Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Mirum Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Mirum Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mirum Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Mirum Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.